Literature DB >> 3902105

Prophylactic effects of neuroleptics in symptom-free schizophrenics: roles of dopaminergic and noradrenergic blockers.

T Nishikawa, A Tsuda, M Tanaka, I Koga, Y Uchida.   

Abstract

A clinical trial was undertaken to determine the role of dopaminergic and noradrenergic blockers in the maintenance treatment of remitted schizophrenics. One hundred and six remitted schizophrenic outpatients were treated with one of nine treatments, viz., thioridazine 25 mg or 75 mg, pimozide 2 mg or 6 mg, and their respective combinations, for 1 year in a double-blind controlled study employing a randomized design. The data from a previous study were utilized as a retrospective placebo group. Pimozide prolonged the number of symptom-free days in a dose-dependent manner and did so more markedly than thioridazine. Combined administration of pimozide and thioridazine prolonged the number of symptom-free days to a greater extent than their single administration. However, an inverted U-shaped dose-response curve was obtained with the combined administration of these agents. These data suggest that both the dopaminergic and noradrenergic blocking action of neuroleptics are important in preventing relapse in remitted schizophrenics.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3902105     DOI: 10.1016/0006-3223(85)90174-x

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  8 in total

1.  Hyperprolactinaemia caused by antipsychotic drugs.

Authors:  Angelika Wieck; Peter Haddad
Journal:  BMJ       Date:  2002-02-02

2.  Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis.

Authors:  Hiroyuki Uchida; Takefumi Suzuki; Hiroyoshi Takeuchi; Tamara Arenovich; David C Mamo
Journal:  Schizophr Bull       Date:  2009-11-27       Impact factor: 9.306

Review 3.  Antipsychotic combinations for schizophrenia.

Authors:  Javier Ortiz-Orendain; Santiago Castiello-de Obeso; Luis Enrique Colunga-Lozano; Yue Hu; Nicola Maayan; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2017-06-28

4.  Cytochrome P450-mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy.

Authors:  Michael Paulzen; Ekkehard Haen; Christoph Hiemke; Benedikt Stegmann; Sarah E Lammertz; Gerhard Gründer; Georgios Schoretsanitis
Journal:  Br J Clin Pharmacol       Date:  2017-03-02       Impact factor: 4.335

5.  Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part I.

Authors:  R Miller
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

6.  Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials.

Authors:  Christoph U Correll; Christine Rummel-Kluge; Caroline Corves; John M Kane; Stefan Leucht
Journal:  Schizophr Bull       Date:  2008-04-15       Impact factor: 9.306

Review 7.  Thioridazine for schizophrenia.

Authors:  M Fenton; J Rathbone; J Reilly; A Sultana
Journal:  Cochrane Database Syst Rev       Date:  2007-07-18

8.  Treatment of acute and transient psychotic disorders with low and high doses of oral haloperidol.

Authors:  A Khanna; N Lal; P K Dalal; A Khalid; J K Trivedi
Journal:  Indian J Psychiatry       Date:  1997-04       Impact factor: 1.759

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.